Targeting the nicotinic acetylcholine receptor is a crucial new direction in the development of antidepressant drugs (nAChR). This receptor, which is extensively distributed in the areas of the brain connected to depression, is also involved in other significant processes that are connected to depression, including stress and inflammation. Mecamylamine- and cytisine-based compounds can be used as a general classification of the two types of medications that target nAChRs. Strong preclinical outcomes support the antidepressant efficacy of both classes when used in conjunction with other primary antidepressants, and these medications likely exert their effects by antagonistically binding to nAChRs at the 42 position (e.g., monoamine reuptake inhibitors). Preliminary findings in this field provide a compelling case for further investigation of the nAChR as a target for the creation of new antidepressant medications, despite the paucity of clinical evidence in this domain. Physiologically based pharmacokinetic (PBPK) modelling is a concept that has been around for a while, although it has not seen much use. The rise in the number of papers in this area, however, indicates that both interest in and use of this modelling technique has grown. The technique, uses, and restrictions of PBPK modelling are briefly illustrated in this work, with a focus on the use of PBPK models in the development of paediatric medications. Several specific examples are also provided. Despite the fact that PBPK models do have significant drawbacks, the technique has a very high potential for success. In order to enhance decision-making during drug discovery, PBPK models can be used to examine drug pharmacokinetics in various physiological and pathological contexts or in various age groups. This is possibly most crucial.
Published Date: 2022-08-29; Received Date: 2022-07-29
